Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
A prospective multicenter surveillance program on yeast bloodstream infections was implemented in the Paris, France, area without restrictions on ward of hospitalization (intensive care unit, hematology, and surgery) or age (adults and children). The present analysis concerns 2,618 isolates collected over 7 years from 2,441 patients. Centralized species identification and antifungal susceptibility testing using the EUCAST methodology were performed. Almost 10% (232/2,441) of the patients had recently (≤30 days) been treated with antifungal drugs. We analyzed the effect of recent exposure to fluconazole ( n = 159) or caspofungin ( n = 61) on the proportions of the five major Candida species. For both drugs, preexposure was associated with a decreased prevalence of Candida albicans in favor of less drug-susceptible species ( C. glabrata and C. krusei for the former and C. parapsilosis and, to a lesser extent, C. glabrata and C. krusei for the latter; P = 0.001). In the multivariate analysis, the risk of being infected with an isolate with decreased susceptibility to fluconazole was independently associated with an age of ≥15 years (odds ratio [OR] = 2.45; 95% confidence interval [CI] = 1.39 to 4.31; P = 0.002) and with recent exposure to fluconazole (OR = 2.17; 95% CI = 1.51 to 3.13; P < 0.001), while the risk of being infected with an isolate with decreased susceptibility to caspofungin was independently associated with an age <15 years (OR = 2.53; 95% CI = 1.43 to 4.48; P = 0.001) and with recent exposure to caspofungin (OR = 4.79; 95% CI = 2.47 to 9.28; P < 0.001). These findings could influence future recommendations for the management of candidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, Candida spp. distribution may not vary only between geographical regions, but even between medical centers in close proximity, perhaps affected by factors influencing local epidemiology including prior antifungal exposure and patient age within the ICU.67”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [67]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent exposure to an echinocandin was found to significantly increase the risk of infection with C. parapsilosis [85].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [85]
In the citing paper
“Often, for naturally susceptible species, both the relative amount of resistant strains and the overall MIC levels in clinical isolates increase after the continuous use of a given antifungal drug [44].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [44]
In the citing paper
“Quite soon after the introduction of the echinocandins it was noted that the increasing use was accompanied by epidemiological shifts with a proportional or numeric increase in the less susceptible C. parapsilosis at several centres (8;17;18).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [8]
In the citing paper
“A consequence of enhanced drug exposure is increased selection pressure for resistance and indeed an altered species distribution for invasive infections has been linked to the echinocandin use (8).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 4×
“ysis of susceptibility profiles can occur (30).”
BackgroundResultInfluentialInternational Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“The 2009 updated guidelines of the Infectious Diseases Society of America (IDSA) recommend that an echinocandin or fluconazole be used as first-line therapy for candidemia before identification of the causative species in nonneutropenic patients (27) and that an echinocandin be used in the case of exposure to fluconaz…”
BackgroundPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“caspofungin or fluconazole, the two major drugs recommended for the first-line treatment of candidemia and for preemptive/ prophylactic treatment in high-risk patients, was associated with changes in the epidemiology of the infection (22, 28).”
BackgroundPosaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“In addition, they have been associated with reduced survival in cancer patients with recent azole administration (17, 38, 45).”
BackgroundWingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species
Abi‐Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., & Vartivarian, S. (1997) · Clinical Infectious Diseases · doi:10.1086/513663 · Cited by 755 · cited 1×
“The relationship between the increased incidence of these species and fluconazole prescription has been debated ever since the introduction of fluconazole as prophylaxis in hematology wards (1, 15, 33, 46) and in ICUs (14).”
BackgroundTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Parczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
Rodriguez-Tudela, J. L., Arendrup, M. C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Denning, D. W., Donnelly, J. P., Dromer, F., et al. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01935.x · Cited by 652
Self-citationHajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 1×
“In addition, they have been associated with reduced survival in cancer patients with recent azole administration (17, 38, 45).”
BackgroundAlmirante, B., Rodríguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1829-1835.2005 · Cited by 566
Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535
Self-citationColombo, A. L., Nucci, M., Park, B. J., Nouér, S. A., Arthington-Skaggs, B., da Matta, D. A., Warnock, D., & Morgan, J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00773-06 · Cited by 526
Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509 · cited 1×
“Of importance, the underlying conditions of the population studied here are representative of all major underlying conditions reported so far for patients with candidemia in various countries (2, 5, 7, 16, 40).”
BackgroundMarr, K. A., Seidel, K., White, T. C., & Bowden, R. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315193 · Cited by 493
Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478 · cited 1×
“However, lack of a shift is also reported (21, 23, 35, 36).”
BackgroundMaertens, J., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W. J., Lass-Flörl, C., Ribaud, P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 470
Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 387
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269 · cited 1×
“to predict treatment efficacy during candidemia (32, 37), de-”
BackgroundPfaller, M. A., Messer, S. A., Boyken, L., Hollis, R. J., Rice, C., Tendolkar, S., & Diekema, D. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.008 · Cited by 234
Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., & Gibbs, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.12.5848-5859.2005 · Cited by 228
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D., Chawla, V., Young, J., & Hadley, S. (2008) · Clinical Infectious Diseases · doi:10.1086/529435 · Cited by 223
Katiyar, S., Pfaller, M., & Edlind, T. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189
Active Surveillance of Candidemia, Australia
Chen, S., Slavin, M., Nguyen, Q., Marriott, D., Playford, E. G., Ellis, D., Sorrell, T., & Study, T. A. C. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1210.060389 · Cited by 174
Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis*
Shorr, A. F., Chung, K., Jackson, W. L., Waterman, P. E., & Kollef, M. H. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000178352.14703.49 · Cited by 166
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death
Slavin, M. A., Sorrell, T. C., Marriott, D., Thursky, K. A., Nguyen, Q., Ellis, D. H., Morrissey, C. O., Chen, S. C. A., & on behalf of the Australian Candidemia Study, A. S. F. I. D. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq053 · Cited by 162
Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.
Playford, E. G., Marriott, D., Nguyen, Q., Chen, S., Ellis, D., Slavin, M., & Sorrell, T. C. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181760f42 · Cited by 156
Lin, M. Y., Carmeli, Y., Zumsteg, J., Flores, E. L., Tolentino, J., Sreeramoju, P., & Weber, S. G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4555-4560.2005 · Cited by 150
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest, G. N., Weekes, E., & Johnson, J. K. (2008) · Journal of Infection · doi:10.1016/j.jinf.2007.10.014 · Cited by 144
Global trends in candidemia: Review of reports from 1995–2005
Morgan, J. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0044-7 · Cited by 139
Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132
Self-citationRisk Factors for Fluconazole-Resistant Candidemia
Garnacho-Montero, J., Díaz-Martín, A., García-Cabrera, E., Ruiz Pérez de Pipaón, M., Hernández-Caballero, C., Aznar-Martín, J., Cisneros, J. M., & Ortiz-Leyba, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00479-10 · Cited by 127
Oxman, D. A., Chow, J. K., Frendl, G., Hadley, S., Hershkovitz, S., Ireland, P., McDermott, L. A., Tsai, K., Marty, F. M., Kontoyiannis, D. P., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq136 · Cited by 105
Shorr, A. F., Lazarus, D. R., Sherner, J. H., Jackson, W. L., Morrel, M., Fraser, V. J., & Kollef, M. H. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000259379.97694.00 · Cited by 101
Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients
Senn, L., Eggimann, P., Ksontini, R., Pascual, A., Demartines, N., Billé, J., Calandra, T., & Marchetti, O. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1405-8 · Cited by 100
EUCAST Technical Note on fluconazole
* (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01899.x · Cited by 94
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit
Bassetti, M., Ansaldi, F., Nicolini, L., Malfatto, E., Molinari, M. P., Mussap, M., Rebesco, B., Bobbio Pallavicini, F., Icardi, G., & Viscoli, C. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp251 · Cited by 92
Risk Factors for Fluconazole-Resistant Candida glabrata Bloodstream Infections
Lee, I., Fishman, N. O., Zaoutis, T. E., Morales, K. H., Weiner, M. G., Synnestvedt, M., Nachamkin, I., & Lautenbach, E. (2009) · Archives of Internal Medicine · doi:10.1001/archinte.169.4.379 · Cited by 81
Bartizal, C., & Odds, F. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2100-2107.2003 · Cited by 60
Rodriguez Tudela, J. L., Donnelly, J. P., Arendrup, M. C., Arikan, S., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, É., Denning, D. W., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02658_1.x · Cited by 36
Lortholary, O., Gangneux, J., Montravers, P., Mira, J. P., Gouin, F., Sollet, J.-P., Carlet, J. M., Reynes, J., Regnier, B., Rosenheim, M., et al. (2008) · HAL · Cited by 25
Self-citation
Research works printed but not linked: 1
- M-1033/523. Abstr. 49th Intersci. Conf. Antimicrob. Chemother. 2009
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“As some NAC species exhibit intrinsic resistance to azoles, their use is likely a contributing factor to the more frequent incidence of infections caused by these NAC species (Oxman et al., 2010; Lortholary et al., 2011; Fothergill et al., 2014).”
Background
Metadata
- Authors
- Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Institut Pasteur, Unité de Mycologie Moléculaire, Centre National de Référence Mycologie et Antifongiques, Paris
- Centre National de la Recherche Scientifique (FR)
- Institut Pasteur (FR)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 532-538
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3028765
- OpenAlex
- W1981025594
- Cited by
- 362
- References
- 47
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 20 · 2023: 18 · 2022: 18 · 2021: 18 · 2020: 31 · 2019: 16 · 2018: 34 · 2017: 30 · 2016: 23 · 2015: 31 · 2014: 41 · 2013: 24 · 2012: 26
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Pfizer
- Gilead Sciences
- Astellas Pharma
- Institut Gustave-Roussy
- Institut de Veille Sanitaire
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, caspofungin, fluconazole, Candida species distribution, Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, antifungal susceptibility, reduced susceptibility, fungemia, epidemiology
- MeSH terms
- Caspofungin, Adult, Antifungal Agents, Candida, Candida albicans, Child, Child, Preschool, Cross Infection, France, Humans, Microbial Sensitivity Tests, Paris, Population Surveillance, Prospective Studies, Species Specificity, Fluconazole, Prevalence, Drug Resistance, Fungal, Echinocandins, Lipopeptides, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.